Results 151 to 160 of about 3,811,568 (245)

Neutropenia in Patients With Castration-Resistant Prostate Cancer Treated Using Cabazitaxel and Prophylactic Administration of Pegfilgrastim. [PDF]

Adv Urol
Oshinomi K, Kikuchi S, Kurokawa M, Mugita T, Inoue T, Yamagishi M, Nakagami Y, Nagata M, Sasaki H, Fuji K, Morita M, Fukagai T.   +11 more
europepmc   +1 more source

The role of molecular profiling for castration-resistant prostate cancer treatment and therapy development. [PDF]

Front Cell Dev Biol
Mann TJ, Becker TM, Roberts TL, de Souza P, Lock JG.   +4 more
europepmc   +1 more source

Precision Targeting in Metastatic Castration-Resistant Prostate Cancer: Advancements in Personalized Therapeutics

International Journal of Medical Students
Background:  Castration-resistant prostate cancer continues to be an incurable and aggressive condition. Enzalutamide; an antiandrogen, shows better radiographic progression-free survival and overall survival in men with metastatic castration ...
ALI HASSAN SALIM KIDIYA, Arshiya ummey, Naga Sai Gouthami Gurujala, Srijamya   +3 more
doaj  

Prostatic Acid Phosphatase (PAP) Antibodies to Treat Castration-Resistant Prostate Cancer. [PDF]

Int J Mol Sci
Kirschenbaum A, Cheung P, Yao S, Duty JA, Kraus T, Moran T, Levine AC.   +6 more
europepmc   +1 more source

Integrated Transcriptomic Analysis Identifies Potential Biomarkers in Castration-Resistant Prostate Cancer. [PDF]

World J Oncol
Naeem AA, Abdulsamad SA, Hayat A, Naeem A, Alhazmi N, Fallata G, Bokhari A, Alharbi AH, Alkinani KA, Alshehri AM, Aldabbagh KM.   +10 more
europepmc   +1 more source

SLPI is associated with AR-regulated epithelial adaptation and enzalutamide sensitivity in castration-resistant prostate cancer. [PDF]

Front Pharmacol
Zhu Z, Shen Y, He X, Zhou M.
europepmc   +1 more source

Tumor‑immune spatiotemporal co‑evolution: A new paradigm for understanding and overcoming therapy resistance in metastatic castration‑resistant prostate cancer (Review). [PDF]

Int J Mol Med
Yan L, Sun X, Su P.
europepmc   +1 more source

Sequential Enzalutamide-Docetaxel Versus Abiraterone-Docetaxel Therapy in Castration-Resistant Prostate Cancer: A Subanalysis of the ENABLE Study. [PDF]

Int J Urol
Kamiyama M, Izumi K, Mitsui T, Shima T, Kato Y, Mita K, Okamura T, Inoue S, Hoshi S, Tanaka N, Yoshio Y, Tatarano S, Chikazawa I, Kawai N, Hashimoto K, Fukagai T, Shigehara K, Takahara S, Mizokami A.   +18 more
europepmc   +1 more source

The role of lysophosphatidic acid metabolism in castration-resistant prostate cancer progression. [PDF]

Front Oncol
Feng J, Liu J, He Y.
europepmc   +1 more source

Myosteatosis Predicts Poor Prognosis in Patients With Castration-Resistant Prostate Cancer Treated With Enzalutamide. [PDF]

Int J Urol
Kanaki T, Hatano K, Oka T, Tani M, Konishi M, Liu Y, Horitani H, Matsukawa A, Inoguchi S, Yoshimura A, Horibe Y, Sassi N, Okuda Y, Ishizuya Y, Hayashi T, Yamamoto Y, Kato T, Kawashima A, Nonomura N.   +18 more
europepmc   +1 more source